Quest Diagnostics Earnings Preview: What to Expect

Core Viewpoint - Quest Diagnostics Incorporated (DGX) is positioned for growth with expected earnings increases and a strong performance relative to market indices [1][5]. Financial Performance - DGX is set to release its Q1 2026 earnings on April 21, with analysts projecting an EPS of $2.35, reflecting a 6.3% increase from $2.21 in the same quarter last year [2]. - For fiscal 2026, the projected EPS is $10.60, up 7.6% from $9.85 in fiscal 2025, with further growth expected to $11.44 in fiscal 2027, representing a year-over-year increase of approximately 7.9% [3]. - The company has consistently exceeded Wall Street's EPS estimates in the last four quarters, with reported EPS figures showing positive surprises [4]. Stock Performance - DGX stock has increased by 18.9% over the past 52 weeks, outperforming the S&P 500 Index's rise of 13.4% [5]. - Following the release of better-than-expected Q4 2025 earnings, DGX stock rose by 7.4%, with revenue surpassing estimates and management raising full-year forecasts [6]. Analyst Sentiment - Analysts maintain a "Moderate Buy" rating on DGX, with nine recommending a "Strong Buy" and nine advising "Hold" [7]. - The average analyst price target for DGX is $218.53, indicating a potential upside of 10.3% from current levels [7].